Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients.
A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be
conducted prior to opening enrollment into the compassionate use study. All patients enrolled
in the safety lead-in study may continue long-term treatment under this protocol without
interruption of dosing.